Immunoglobulin G replacement for the treatment of infective complications of rituximab-associated hypogammaglobulinemia in autoimmune disease: A case series
The anti-CD20 B cell depleting monoclonal antibody rituximab is being used increasingly for autoimmune diseases, including patients with refractory disease with extensive prior exposure to immunosuppressive treatments. Rituximab, in this context, may be associated with increased risk of adverse effects, in particular hypogammaglobulinemia which predisposes to recurrent infections necessitating Immunoglobulin G replacement. Outcome data following Immunoglobulin G replacement after rituximabin...[Show more]
|Collections||ANU Research Publications|
|Source:||Journal of Autoimmunity|
|01_Roberts_Immunoglobulin_G_replacement_2015.pdf||246.55 kB||Adobe PDF||Request a copy|
Items in Open Research are protected by copyright, with all rights reserved, unless otherwise indicated.